|
199 Companies |
|
329 Products |
|
329 Products |
|
164 Mechanisms of Action |
|
13 Trials |
|
3299 News |
|
| «12...56789101112131415...6768» |
- ||||||| bortezomib / Generic mfg., dexamethasone / Generic mfg.
Trial completion: A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039 (clinicaltrials.gov) - Feb 6, 2017
P3, N=600, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
No longer recruiting --> Completed
- Enrollment change, Trial withdrawal: Single Incision Versus Standard Laparoscopic Splenectomy (clinicaltrials.gov) - Feb 3, 2017
P=N/A, N=0, Withdrawn, Sponsor: Children's Mercy Hospital Kansas City
No longer recruiting --> Completed N=30 --> 0 | Active, not recruiting --> Withdrawn
- | Trial completion, Heterogeneity: Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function (clinicaltrials.gov) - Feb 3, 2017
P=N/A, N=42, Completed, Sponsor: CancerCare Manitoba
N=30 --> 0 | Active, not recruiting --> Withdrawn Active, not recruiting --> Completed
- Trial termination: Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 3, 2017
P=N/A, N=30, Terminated, Sponsor: Rutgers, The State University of New Jersey
Active, not recruiting --> Completed Active, not recruiting --> Terminated; slow accrual
- | Promacta (eltrombopag) / Novartis
Enrollment closed, Enrollment change, Trial primary completion date: Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients (clinicaltrials.gov) - Feb 2, 2017
P2, N=19, Active, not recruiting, Sponsor: Weill Medical College of Cornell University
Active, not recruiting --> Terminated; slow accrual Recruiting --> Active, not recruiting | N=50 --> 19 | Trial primary completion date: Jun 2013 --> May 2019
- | Promacta (eltrombopag) / Novartis
Trial completion, Trial initiation date, Trial primary completion date: Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Feb 2, 2017
P2, N=12, Completed, Sponsor: Weill Medical College of Cornell University
Recruiting --> Active, not recruiting | N=50 --> 19 | Trial primary completion date: Jun 2013 --> May 2019 Active, not recruiting --> Completed | Initiation date: May 2009 --> Jan 2009 | Trial primary completion date: Jan 2014 --> Sep 2015
- Promacta (eltrombopag) / Novartis
Trial primary completion date: End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia (clinicaltrials.gov) - Feb 2, 2017
P=N/A, N=20, Recruiting, Sponsor: Weill Medical College of Cornell University
Active, not recruiting --> Completed | Initiation date: May 2009 --> Jan 2009 | Trial primary completion date: Jan 2014 --> Sep 2015 Trial primary completion date: Jun 2013 --> Mar 2019
- | Rituxan (rituximab) / Roche
Trial initiation date: Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune Thrombocytopenia (clinicaltrials.gov) - Feb 2, 2017
P3, N=182, Not yet recruiting, Sponsor: Weill Medical College of Cornell University
Trial primary completion date: Jun 2013 --> Mar 2019 Initiation date: Jun 2016 --> Jun 2019
- Phase classification: Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay (clinicaltrials.gov) - Feb 1, 2017
P=N/A, N=7, Completed, Sponsor: Children's Hospital Los Angeles
Initiation date: Jun 2016 --> Jun 2019 Phase classification: P1/2 --> P=N/A
- || lenalidomide / Generic mfg., sirolimus / Generic mfg.
Trial primary completion date: Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM) (clinicaltrials.gov) - Feb 1, 2017
P1/2, N=53, Active, not recruiting, Sponsor: Sherif S. Farag
Phase classification: P1/2 --> P=N/A Trial primary completion date: Dec 2016 --> Dec 2017
- Trial primary completion date: ACUFOCIN: Standard Care Alone or With Acupuncture for CIPN in Breast Cancer and Multiple Myeloma (clinicaltrials.gov) - Feb 1, 2017
P2, N=120, Recruiting, Sponsor: The Christie NHS Foundation Trust
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Dec 2016 --> Apr 2017
- tranexamic acid oral / Generic mfg.
Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: The Assessment of Tranexamic Acid in Women With Menorrhagia Who Have Bleeding Disorders (clinicaltrials.gov) - Jan 31, 2017
P4, N=249, Completed, Sponsor: K. Sue Robinson
Trial primary completion date: Dec 2016 --> Apr 2017 Not yet recruiting --> Completed | N=149 --> 249 | Initiation date: Jun 2009 --> Oct 2009 | Trial primary completion date: Jun 2010 --> Mar 2014
- Trial primary completion date: MCSF-MYELOME: Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma (clinicaltrials.gov) - Jan 31, 2017
P=N/A, N=200, Recruiting, Sponsor: Centre Hospitalier Universitaire, Amiens
Not yet recruiting --> Completed | N=149 --> 249 | Initiation date: Jun 2009 --> Oct 2009 | Trial primary completion date: Jun 2010 --> Mar 2014 Trial primary completion date: Dec 2016 --> Dec 2018
- | RiaSTAP (fibrinogen concentrate (human)) / CSL Behring
Trial completion, Surgery: Fibrinogen as an Alternative to FFP in Aortic Surgery. (clinicaltrials.gov) - Jan 31, 2017
P4, N=20, Completed, Sponsor: University of Edinburgh
Trial primary completion date: Dec 2016 --> Dec 2018 Recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial primary completion date: Dex/Rituxan: A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone (clinicaltrials.gov) - Jan 31, 2017
P=N/A, N=50, Recruiting, Sponsor: Weill Medical College of Cornell University
Recruiting --> Completed Trial primary completion date: Jan 2016 --> Jun 2017
- || Venclexta (venetoclax) / Roche, AbbVie, azintuxizumab vedotin (ABBV-838) / AbbVie
Trial initiation date, Combination therapy: A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment (clinicaltrials.gov) - Jan 31, 2017
P1b, N=72, Not yet recruiting, Sponsor: AbbVie
Trial primary completion date: Jan 2016 --> Jun 2017 Initiation date: Nov 2016 --> May 2017
- | Farydak (panobinostat) / Secura Bio
Trial completion, Combination therapy: Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM) (clinicaltrials.gov) - Jan 30, 2017
P2, N=29, Completed, Sponsor: Ajai Chari
Initiation date: Nov 2016 --> May 2017 Active, not recruiting --> Completed
- dinaciclib (MK-7965) / Merck (MSD)
Enrollment closed, Combination therapy: Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma (clinicaltrials.gov) - Jan 30, 2017
P1, N=40, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Suspended --> Active, not recruiting
- bortezomib / Generic mfg.
Trial completion, Trial primary completion date, Combination therapy: Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma (clinicaltrials.gov) - Jan 30, 2017
P1, N=10, Completed, Sponsor: Washington University School of Medicine
Suspended --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Apr 2017 --> Jul 2016
- ||| Xyntha (moroctocog alfa) / Pfizer
New trial: Post-Marketing Surveillance To Observe Safety And Efficacy Of Xyntha Solofuse Prefilled Syringe (clinicaltrials.gov) - Jan 30, 2017
P=N/A, N=600, Not yet recruiting, Sponsor: Pfizer
- || lenalidomide / Generic mfg.
Enrollment closed: A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID (clinicaltrials.gov) - Jan 26, 2017
P=N/A, N=624, Active, not recruiting, Sponsor: Celgene
Recruiting --> Completed | Trial primary completion date: Apr 2017 --> Jul 2016 Recruiting --> Active, not recruiting
- || Trial primary completion date: A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (? 65 Years) With Haematologic Neoplasms (clinicaltrials.gov) - Jan 26, 2017
P=N/A, N=80, Recruiting, Sponsor: Celgene
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2016 --> Feb 2017
- Trial primary completion date: Study of the Immune Response After Vaccination in Multiple Myeloma Patients (clinicaltrials.gov) - Jan 24, 2017
P=N/A, N=19, Active, not recruiting, Sponsor: Michael A. Thompson, MD, PhD
Trial primary completion date: Nov 2016 --> Feb 2017 Trial primary completion date: Dec 2016 --> Nov 2017
- |||| rocilinostat (ACY-1215) / Regenacy
Trial completion, Trial primary completion date, Combination therapy, Monotherapy: Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma (clinicaltrials.gov) - Jan 24, 2017
P1/2, N=120, Completed, Sponsor: Acetylon Pharmaceuticals Incorporated
Trial primary completion date: Dec 2016 --> Nov 2017 Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Dec 2016
- || Xyntha (moroctocog alfa) / Pfizer
Enrollment closed, Trial primary completion date, Adverse events: Study Evaluating Pharmacovigilance Of Refacto AF (clinicaltrials.gov) - Jan 24, 2017
P=N/A, N=140, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Dec 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2017 --> Oct 2016
- || bortezomib / Generic mfg., pegylated liposomal doxorubicin / Generic mfg., bendamustine / Generic mfg.
Trial primary completion date, Combination therapy: Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma (clinicaltrials.gov) - Jan 23, 2017
P1/2, N=69, Active, not recruiting, Sponsor: Sherif Farag, MB, BS
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2017 --> Oct 2016 Trial primary completion date: Dec 2016 --> Jun 2017
- Enrollment change: Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jan 23, 2017
P1, N=18, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
Trial primary completion date: Dec 2016 --> Jun 2017 N=24 --> 18
- everolimus / Generic mfg., bendamustine / Generic mfg.
Trial primary completion date: Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer (clinicaltrials.gov) - Jan 23, 2017
P1, N=18, Recruiting, Sponsor: University of California, Davis
N=24 --> 18 Trial primary completion date: Dec 2016 --> Dec 2017
- Clinical: UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination (clinicaltrials.gov) - Jan 23, 2017
P2, N=0, Withdrawn, Sponsor: University of Arkansas
Trial primary completion date: Dec 2016 --> Dec 2017 N=30 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2018 --> Jan 2017
- ||| dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Trial completion, Trial primary completion date: LEGEND: A Retrospective Chart Review Study of the Outcomes of 2nd Line Therapy With LEn/Dex in Greek Patients With R/R Multiple MyEloma and the Treatment PatterNs Following Progressive Disease (clinicaltrials.gov) - Jan 19, 2017
P=N/A, N=207, Completed, Sponsor: Genesis Pharma S.A.
N=30 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2018 --> Jan 2017 Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Sep 2016
- |||| Trial completion, Trial primary completion date: Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone (clinicaltrials.gov) - Jan 18, 2017
P2b, N=250, Completed, Sponsor: PETHEMA Foundation
Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Sep 2016 Active, not recruiting --> Completed | Trial primary completion date: Nov 2015 --> Aug 2014
- aspirin / Generic mfg., hydroxyurea / Generic mfg.
Trial completion, Trial primary completion date: Primary Thrombocythaemia 1 Trial (clinicaltrials.gov) - Jan 18, 2017
P=N/A, N=1398, Completed, Sponsor: University of Cambridge
Active, not recruiting --> Completed | Trial primary completion date: Nov 2015 --> Aug 2014 Active, not recruiting --> Completed | Trial primary completion date: Apr 2024 --> Nov 2016
- | Jakafi (ruxolitinib) / Novartis, Incyte
Enrollment closed, Enrollment change: Ruxolitinib Prior to Transplant in Patients With Myelofibrosis (clinicaltrials.gov) - Jan 18, 2017
P2, N=21, Active, not recruiting, Sponsor: John Mascarenhas
Active, not recruiting --> Completed | Trial primary completion date: Apr 2024 --> Nov 2016 Recruiting --> Active, not recruiting | N=86 --> 21
- Trial completion, Trial primary completion date: DMSOconc3: Impact of DMSO Concentrations on Hematopoietic Recovery After Autologous HSC Transplantation. (clinicaltrials.gov) - Jan 18, 2017
P=N/A, N=150, Completed, Sponsor: Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology
Recruiting --> Active, not recruiting | N=86 --> 21 Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Aug 2016
- | Opdivo (nivolumab) / Ono Pharma, BMS
Clinical: Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma (clinicaltrials.gov) - Jan 18, 2017
P1, N=40, Not yet recruiting, Sponsor: PETHEMA Foundation
- prednisone / Generic mfg., cyclosporin A microemulsion / Generic mfg., hydrocortisone / Generic mfg.
Trial primary completion date: Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP) (clinicaltrials.gov) - Jan 17, 2017
P3, N=62, Active, not recruiting, Sponsor: Ohio State University
Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Aug 2016 Trial primary completion date: Oct 2016 --> Jun 2017
- pegylated liposomal doxorubicin / Generic mfg., carfilzomib / Generic mfg.
Clinical: Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jan 13, 2017
P1/2, N=40, Active, not recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Oct 2016 --> Jun 2017 Recruiting --> Active, not recruiting | N=53 --> 40 | Trial primary completion date: Feb 2017 --> Sep 2018
- bortezomib / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma (clinicaltrials.gov) - Jan 13, 2017
P2, N=10, Completed, Sponsor: University of Arkansas
Recruiting --> Active, not recruiting | N=53 --> 40 | Trial primary completion date: Feb 2017 --> Sep 2018 Recruiting --> Completed | N=30 --> 10 | Trial primary completion date: Dec 2017 --> Oct 2016
- | NovoSeven (eptacog alfa) / Novo Nordisk
Trial completion, Surgery: Use of Activated Recombinant FVII in Spinal Surgery (clinicaltrials.gov) - Jan 12, 2017
P2, N=50, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Completed | N=30 --> 10 | Trial primary completion date: Dec 2017 --> Oct 2016 No longer recruiting --> Completed
- alisertib (MLN8237) / Puma, Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jan 12, 2017
P2, N=50, Active, not recruiting, Sponsor: Kristie Blum
No longer recruiting --> Completed Trial primary completion date: Dec 2016 --> Oct 2015
- lenalidomide / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide) (clinicaltrials.gov) - Jan 12, 2017
P=N/A, N=176, Terminated, Sponsor: Celgene
Trial primary completion date: Dec 2016 --> Oct 2015 N=300 --> 176 | Recruiting --> Terminated | Trial primary completion date: Nov 2016 --> Jul 2016; Business Decision
- Phase classification: MRA With Feraheme in HHT (clinicaltrials.gov) - Jan 12, 2017
P1, N=10, Recruiting, Sponsor: University of California, Los Angeles
N=300 --> 176 | Recruiting --> Terminated | Trial primary completion date: Nov 2016 --> Jul 2016; Business Decision Phase classification: P=N/A --> P1
- ||||||| NovoSeven (eptacog alfa) / Novo Nordisk
Trial completion: FAST: Recombinant Factor VIIa in Acute Intracerebral Haemorrhage (clinicaltrials.gov) - Jan 11, 2017
P3, N=829, Completed, Sponsor: Novo Nordisk A/S
Phase classification: P=N/A --> P1 No longer recruiting --> Completed
- |||| NovoSeven (eptacog alfa) / Novo Nordisk
Trial completion: Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury (clinicaltrials.gov) - Jan 11, 2017
P2, N=96, Completed, Sponsor: Novo Nordisk A/S
No longer recruiting --> Completed No longer recruiting --> Completed
- | NovoSeven (eptacog alfa) / Novo Nordisk
Trial completion: Trial of NovoSeven® in Haemophilia - Joint Bleeds (clinicaltrials.gov) - Jan 11, 2017
P4, N=42, Completed, Sponsor: Novo Nordisk A/S
No longer recruiting --> Completed Recruiting --> Completed
- | NovoSeven (eptacog alfa) / Novo Nordisk
Trial completion: Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia (clinicaltrials.gov) - Jan 11, 2017
P2, N=23, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Completed No longer recruiting --> Completed
- ||||| Pegasys (pegylated interferon α -2a) / Roche
Enrollment closed, Enrollment change, Trial primary completion date: Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) (clinicaltrials.gov) - Jan 11, 2017
P3, N=168, Active, not recruiting, Sponsor: Ronald Hoffman
No longer recruiting --> Completed Recruiting --> Active, not recruiting | N=300 --> 168 | Trial primary completion date: Jun 2024 --> Jun 2017
- |||| Pegasys (pegylated interferon α -2a) / Roche
Trial completion, Enrollment change, Trial primary completion date: Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) (clinicaltrials.gov) - Jan 11, 2017
P2, N=135, Completed, Sponsor: Ronald Hoffman
Recruiting --> Active, not recruiting | N=300 --> 168 | Trial primary completion date: Jun 2024 --> Jun 2017 Recruiting --> Completed | N=188 --> 135 | Trial primary completion date: Jun 2018 --> Dec 2016
- ||| NovoSeven (eptacog alfa) / Novo Nordisk
Trial completion, Biopsy: Dose Response to Recombinant Factor VIIa When Administered for Bleed (clinicaltrials.gov) - Jan 11, 2017
P1, N=64, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Completed | N=188 --> 135 | Trial primary completion date: Jun 2018 --> Dec 2016 No longer recruiting --> Completed
- Phase classification, Post-transplantation: Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies (clinicaltrials.gov) - Jan 11, 2017
P1, N=22, Completed, Sponsor: Sally Arai
No longer recruiting --> Completed Phase classification: P1/2 --> P1